Avantor® to Boost Global Production of Single­-Use Technologies and Address Growing Biopharma Demand

Rhea-AI Summary

Avantor Inc. (NYSE: AVTR) announced plans to enhance its global capacity for single-use technologies crucial in biologics and vaccine production. This expansion includes a 30% increase in manufacturing footprint and a doubling of cleanroom space across the U.S. and Europe, responding to rising demand for monoclonal antibodies, gene therapies, and COVID-19 vaccines. Recent expansions include its North Carolina facility and a new cleanroom in Devens, Massachusetts, expected by mid-year. A second European facility will also open in the Netherlands, ensuring efficient supply to biopharma clients.

Positive

• 30% increase in single-use manufacturing footprint.
• Doubling of cleanroom space enhances production capabilities.
• Expansion aligns with rising demand for monoclonal antibodies and gene therapies.

Negative

• None.

RADNOR, Pa., April 26, 2021 /PRNewswire/ -- Avantor Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced that it will increase global capacity for high-quality single-use technologies used in the production of biologics and vaccines.

Dr. Brophy: Biopharma looks to Avantor to know and support requirements as they rapidly expand manufacturing capacity

In the U.S. and Europe, the Company will increase its single-use manufacturing footprint by 30% and double its cleanroom space. The investment will support growing customer demand for monoclonal antibodies (mAbs), novel cell and gene therapies for oncology and other diseases, as well as vaccines, including those for COVID-19.

Avantor recently expanded its Morrisville, North Carolina, single-use facility and expects completion of a cleanroom expansion at its Devens, Massachusetts, operation by mid-year. The Company also expects to open its second European single-use facility in Hillegom, the Netherlands, by then as well.

Dr. Ger Brophy, Executive Vice President of Biopharma Production at Avantor, said, "The industry's response to the COVID-19 pandemic has relied heavily on the integration of single-use products into biopharma production processes. Efficacy and safety are of the utmost importance to our customers, and they look to us to understand and support their requirements as they rapidly expand their own manufacturing capacity.

"These additions to our global single-use manufacturing ecosystem are critical steps in enabling our customers to get therapies to patients quickly," Brophy added.

The investment further strengthens the Company's single-use network, providing product consistency and capabilities close to bioproduction customers to help ensure efficient and uninterrupted supply.

Watch this video for more information about how Avantor's single-use solutions support biopharma manufacturing.

About Avantor
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, visit avantorsciences.com and find us on LinkedIn, Twitter and Facebook.

Global Media Contact 
Robert Donohoe 
Senior Director, Corporate Communications  
Avantor 
M: 484-688-4730 
Robert.Donohoe@avantorsciences.com

View original content:http://www.prnewswire.com/news-releases/avantor-to-boost-global-production-of-single-use-technologies-and-address-growing-biopharma-demand-301276964.html

SOURCE Avantor and Financial News

FAQ

What is Avantor Inc. expanding?

Avantor Inc. is expanding its global capacity for single-use technologies used in biologics and vaccine production.

How much will Avantor increase its manufacturing footprint?

Avantor will increase its single-use manufacturing footprint by 30%.

What are the key areas of demand driving Avantor's expansion?

The expansion is driven by demand for monoclonal antibodies, gene therapies, and vaccines.

When is Avantor's cleanroom expansion expected to be completed?

The cleanroom expansion at Avantor's Devens, Massachusetts facility is expected to be completed by mid-year.

Where will Avantor open its second European facility?

Avantor will open its second European single-use facility in Hillegom, the Netherlands.